Stealth Elamipretide NDA Tests Frontiers Of US FDA’s Flexibility In Rare Diseases

FDA wants another trial in ultra-orphan Barth syndrome, but could not identify a feasible design – so Stealth submitted the NDA anyways, based on a retrospective natural history control trial

Is Stealth BioTherapeutics regulatory strategy for its elamipretide NDA beautiful or dangerous? • Source: Alamy

Stealth BioTherapeutics Inc. is gambling that Barth syndrome patients and advocates can help carry its NDA for elamipretide forward despite the US FDA’s recommendation that a second clinical trial be conducted before submission.

More from Rare Diseases

EU HTA Regulation: Companies Can Talk To National Authorities As ‘Substitute’ For EU-Level Advice

 

Not all companies will be able to access joint scientific consultations under the EU Health Technology Assessment Regulation, but success is still possible for those that engage with national agencies early on, says EUCOPE’s Alexander Natz.

German, Dutch And Italian HTA Processes Not Supportive Of RWD, Say Companies

 

Payers and health technology assessment bodies in the Netherlands, Germany and Italy are either unwilling to use real-world data in assessments or cannot due to their existing frameworks, say representatives from Gilead Sciences and Autolus Therapeutics.

Last Chance For Pharma To Respond To EU Strategy For Reforming Ecosystem For SMEs

 

Companies have until 17 March to respond to an EU consultation on a new strategy that will seek to simplify the regulatory framework and make it easier for innovative small and medium-sized enterprises to “access the capital they need” to scale up in the bloc.

CBER’s Marks Says US FDA’s Rare Disease Work Expected To Win Trump Administration Support

 
• By 

Center for Biologics Evaluation and Research Director Peter Marks expects no fundamental changes in support for FDA initiatives and said the Rare Disease Innovation Hub, which promotes cross-center collaboration, is “consistent with what we're hearing in the current environment.”

More from Pink Sheet

England’s NICE Wants Industry Involvement In HTA Sandbox Projects

 

Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.

Brazil Catches Up With International Standards on Viral Safety Evaluations For Biotech Products

 

The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.

Korea To Revise ‘Innovative Company’ Criteria Amid Calls From Foreign Industry

 
• By 

South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.